Details of the Drug Reposition

General Information of This Drug (ID: DML1KTO)

Drug Name
Belzutifan   DML1KTO
Synonyms MK-6482; PT2977
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Von hippel-lindau disease DIS6ZFQQ 5A75 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Renal cell carcinoma DISQZ2X8 2C90 Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 215383.
2 ClinicalTrials.gov (NCT04586231) A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)